Ovesco Endoscopy AG appears in FDA 510(k) records as the legal applicant for endoscopic devices intended for the gastrointestinal tract. Two substantial-equivalence decisions are documented in the supplied filings, both under product code PKL and both listing an applicant address in Tuebingen, Germany. The company describes itself as a research-based developer, manufacturer and marketer of instruments and systems for gastrointestinal disease, with endoscopic clipping systems as its stated product platform. The filings and company materials together identify the stentFIX System and the FTRD System as named products, while the OTSC platform is described as the basis for related procedures. [1][2][5][8]

The applicant identity in FDA records

Both supplied 510(k) records name Ovesco Endoscopy AG as the applicant, with a Friedrich-Miescher-Strasse 9 address in Tuebingen, Germany, and both carry a decision of substantially equivalent. The two records share product code PKL, regulation number 876.4400 and a Gastroenterology, Urology advisory committee assignment. The filing address is a correspondence address in the records and is not treated here as a headquarters designation. No parent company, brand owner or corporate affiliate is verified in the public documents. [1][2]

The company's own materials describe Ovesco Endoscopy AG as headquartered in Tuebingen, Germany, with additional locations listed in Cary in the United States, Rennes in France and Chennai in India. Those location statements come from the company's product catalog and are attributed to that publisher rather than to an independent source. [5]

Documented products and technology

The stentFIX System is described by the company as a solution for fixing metal stents in the digestive tract, usable with self-expanding metal stents. Company material describes a clip design for wall adaptation, proximal and distal fixation, and a dedicated cap shape for positioning, with an application example placing part of the clip on the stent mesh and part on tissue. The FDA record lists the cleared device as the stentFIX System Set (100.50n). [1][4][6]

The FTRD System appears in the second filing as three named sets: colonic FTRD Set (200.70), diagnostic FTRD Set (200.76) and gastroduodenal FTRD Set (200.72). The company catalog lists the FTRD System among its products alongside the OTSC neo System, stentFIX System, BARS, remOVE System, ScopeCaps and RESECT+. The stentfix OTSC System is described by the company as a specially designed OTSC System labeled for fixation of self-expanding metallic stents, with a round clip design and modified cap shape. [2][5][7]

Dated filing examples and collection scope

The stentFIX System Set (100.50n) filing, K260487, was received on 13 February 2026 and decided on 2 October 2026 as a Traditional 510(k) with a Summary statement. The FTRD Set filing, K253481, was received on 14 October 2025 and decided on 14 September 2026, also Traditional with a Summary statement. Neither filing carries a third-party review flag. [1][2]

The supplied collection contains two linked 510(k) records, both with a substantially equivalent decision, and the record sample likewise contains two substantially equivalent entries. These counts describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1][2]

How the company describes its work

Ovesco describes its core competence as developing endoluminal procedures and technologies for gastrointestinal disease, and states that it develops, manufactures and markets instruments and systems for treatment of gastrointestinal diseases. The company also states that it offers procedures rather than products alone and supports users from training to intervention. These are company statements attributed to Ovesco's own published pages and catalog. [5][8][10]